Cocrystal Pharma Inc
NASDAQ:COCP

Watchlist Manager
Cocrystal Pharma Inc Logo
Cocrystal Pharma Inc
NASDAQ:COCP
Watchlist
Price: 1.07 USD 0.94%
Market Cap: 14.7m USD

Cocrystal Pharma Inc
Other Operating Expenses

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Cocrystal Pharma Inc
Other Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Cocrystal Pharma Inc
NASDAQ:COCP
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Other Operating Expenses
$1.2B
CAGR 3-Years
-22%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Other Operating Expenses
$2B
CAGR 3-Years
-1%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Other Operating Expenses
$196m
CAGR 3-Years
-58%
CAGR 5-Years
-11%
CAGR 10-Years
-14%
Merck & Co Inc
NYSE:MRK
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eli Lilly and Co
NYSE:LLY
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cocrystal Pharma Inc
Glance View

Market Cap
14m USD
Industry
Pharmaceuticals

Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. The company is headquartered in Bothell, Washington and currently employs 13 full-time employees. The company went IPO on 2018-03-12. The firm focuses on developing antiviral therapeutics that inhibit the essential viral replication function of RNA viruses causing acute and chronic viral diseases. The firm focuses on treating influenza virus, coronavirus, hepatitis C virus (HCV) and norovirus infections by discovering and developing drug candidates targeting the viral replication process. The firm uses computational methods to screen and design product candidates using cocrystal structural information. Its development pipeline includes CC-31244 and CC-42344. The Company’s CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. The Company’s CC-42344 is a PB2 inhibitor for the treatment of influenza A infection. Its pipeline also includes CDI-45205 for the treatment of coronavirus. The company has also developed chemical libraries consisting of non-nucleoside inhibitors, metal-binding inhibitors, and drug-like fragments.

COCP Intrinsic Value
HIDDEN
Show

See Also

Back to Top